Rezolute, Inc. (RZLT)
NASDAQ:RZLT
Want to see RZLT full AI Analyst Report?
RZLT Stock Chart & Stats
$3.46
-$0.34(-6.35%)
At close: 4:00 PM EST
$3.46
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$1.07 - $11.46
Previous CloseN/A
Volume107.87K
Average Volume (3M)1.49M
Market Cap
$385.17M
Enterprise Value$307.64M
Total Cash (Recent Filing)$120.27M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Sep 10, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding96,292,330
10 Day Avg. Volume1,721,810
30 Day Avg. Volume1,493,103
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.38K
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$8.00Price Target Upside131.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Interim Phase 3 UpLIFT Data For ErsodetugRobust interim efficacy and tolerability in a severe, unmet tumor hyperinsulinism population establishes clinical proof-of-concept for ersodetug. Durable clinical signal plus patient continuation to long-term extension strengthens the case for regulatory filings, partnerships, and downstream commercial potential.
Constructive FDA Engagement On SunRIZEActive, substantive FDA dialogue reduces binary uncertainty by clarifying evidence expectations. A requested comprehensive submission creates a defined regulatory pathway that can enable approval via review of existing datasets rather than mandating a full new pivotal trial, materially affecting program timelines and development cost.
Conservatively Levered Balance Sheet With Very Low DebtVery low leverage gives Rezolute durable financial flexibility to run clinical programs without immediate debt-servicing constraints. This structural strength lowers near-term default/refinancing risk, preserving strategic options for licensing, R&D sequencing, or negotiating partnership terms while development milestones are pursued.
Bears Say
No Commercial Revenue; Widening Net LossesPersistent pre-revenue status and expanding losses mean the company lacks internal cash generation to fund operations long-term. Structural unprofitability increases reliance on external capital, raises dilution risk for shareholders, and constrains investment flexibility for pipeline expansion or commercialization build-out.
SunRIZE Failed Primary Endpoint, Raising Regulatory RiskA failed primary endpoint is a structural program risk: it complicates regulatory acceptance, may require additional trials or detailed rebuttal packages, and lengthens timelines. This elevates probability of expensive extra studies or limited label scope, materially affecting potential market access and revenue prospects for ersodetug.
High Dependence On External FinancingReliance on equity raises continual funding pressure, especially as cash burn accelerates. Structural dependence on capital markets can force dilution, delay programs if conditions tighten, and limit bargaining power in partnerships, affecting long-term ability to sustain multiple development programs concurrently.
Rezolute News
RZLT FAQ
What was Rezolute, Inc.’s price range in the past 12 months?
Rezolute, Inc. lowest stock price was $1.07 and its highest was $11.46 in the past 12 months.
What is Rezolute, Inc.’s market cap?
Rezolute, Inc.’s market cap is $385.17M.
When is Rezolute, Inc.’s upcoming earnings report date?
Rezolute, Inc.’s upcoming earnings report date is Sep 10, 2026 which is in 97 days.
How were Rezolute, Inc.’s earnings last quarter?
Rezolute, Inc. released its earnings results on May 12, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.181 by $0.021.
Is Rezolute, Inc. overvalued?
According to Wall Street analysts Rezolute, Inc.’s price is currently Undervalued.
Does Rezolute, Inc. pay dividends?
Rezolute, Inc. does not currently pay dividends.
What is Rezolute, Inc.’s EPS estimate?
Rezolute, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Rezolute, Inc. have?
Rezolute, Inc. has 96,292,330 shares outstanding.
What happened to Rezolute, Inc.’s price movement after its last earnings report?
Rezolute, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.181. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of Rezolute, Inc.?
Currently, no hedge funds are holding shares in RZLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rezolute Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (131.21% Upside)
$8.00 (131.21% Upside)
Blogger Sentiment
Neutral
RZLT Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 137.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.61%
12-Months-Change
Fundamentals
Return on Equity
-58.82%
Trailing 12-Months
Asset Growth
32.43%
Trailing 12-Months
Company Description
Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
RZLT Stock 12 Month Forecast
Average Price Target
$8.00
▲(131.21% Upside)
Technical Analysis
Ownership Overview
10.88% Insiders
32.67% Mutual Funds
33.54% Other Institutional Investors
14.08% Public Companies and
Individual Investors